Concepts (110)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 11 | 2024 | 914 | 4.350 |
Why?
|
| Graft vs Host Disease | 4 | 2023 | 362 | 2.250 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2024 | 232 | 2.180 |
Why?
|
| Transplantation, Autologous | 4 | 2021 | 351 | 1.060 |
Why?
|
| Geriatric Assessment | 2 | 2024 | 185 | 0.990 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2024 | 802 | 0.990 |
Why?
|
| Sarcopenia | 1 | 2023 | 13 | 0.860 |
Why?
|
| Primary Myelofibrosis | 1 | 2022 | 67 | 0.760 |
Why?
|
| Quality of Life | 2 | 2020 | 1688 | 0.740 |
Why?
|
| Transplantation Conditioning | 2 | 2022 | 378 | 0.710 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2024 | 361 | 0.700 |
Why?
|
| Hematopoiesis | 1 | 2020 | 169 | 0.660 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 125 | 0.650 |
Why?
|
| POEMS Syndrome | 1 | 2018 | 2 | 0.640 |
Why?
|
| Polyneuropathies | 1 | 2018 | 27 | 0.610 |
Why?
|
| Muscle Weakness | 1 | 2018 | 62 | 0.610 |
Why?
|
| Leg | 1 | 2018 | 140 | 0.610 |
Why?
|
| Immunoglobulins | 1 | 2018 | 143 | 0.600 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 202 | 0.560 |
Why?
|
| Telemedicine | 1 | 2020 | 196 | 0.550 |
Why?
|
| Transplantation, Homologous | 3 | 2022 | 1001 | 0.490 |
Why?
|
| Pandemics | 1 | 2021 | 788 | 0.470 |
Why?
|
| Mastoiditis | 1 | 2013 | 4 | 0.440 |
Why?
|
| Otitis Externa | 1 | 2013 | 5 | 0.440 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2013 | 14 | 0.440 |
Why?
|
| Abscess | 1 | 2013 | 95 | 0.420 |
Why?
|
| Diabetes Complications | 1 | 2013 | 172 | 0.400 |
Why?
|
| Antigens, CD34 | 2 | 2022 | 161 | 0.390 |
Why?
|
| Neoplasm, Residual | 2 | 2024 | 185 | 0.380 |
Why?
|
| Humans | 20 | 2024 | 90568 | 0.370 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2024 | 419 | 0.370 |
Why?
|
| Survival Analysis | 2 | 2022 | 1499 | 0.280 |
Why?
|
| Disease Progression | 2 | 2021 | 1485 | 0.260 |
Why?
|
| Aged | 6 | 2024 | 19404 | 0.240 |
Why?
|
| Male | 8 | 2024 | 42931 | 0.240 |
Why?
|
| Mutation | 3 | 2024 | 4184 | 0.230 |
Why?
|
| CD47 Antigen | 1 | 2024 | 23 | 0.230 |
Why?
|
| Medical Futility | 1 | 2024 | 31 | 0.220 |
Why?
|
| Transplantation, Haploidentical | 1 | 2023 | 28 | 0.220 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 92 | 0.220 |
Why?
|
| Nutritional Status | 1 | 2023 | 81 | 0.210 |
Why?
|
| Tissue Distribution | 1 | 2023 | 293 | 0.210 |
Why?
|
| Body Composition | 1 | 2023 | 73 | 0.210 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 303 | 0.210 |
Why?
|
| Sulfonamides | 1 | 2024 | 320 | 0.190 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 175 | 0.190 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 594 | 0.190 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2021 | 4 | 0.180 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2021 | 10 | 0.180 |
Why?
|
| Civil Defense | 1 | 2021 | 11 | 0.180 |
Why?
|
| New York City | 1 | 2021 | 61 | 0.180 |
Why?
|
| Anemia, Aplastic | 1 | 2021 | 32 | 0.180 |
Why?
|
| Adult | 6 | 2024 | 26940 | 0.180 |
Why?
|
| Evidence-Based Practice | 1 | 2021 | 48 | 0.180 |
Why?
|
| Middle Aged | 5 | 2024 | 26327 | 0.180 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 406 | 0.180 |
Why?
|
| Resource Allocation | 1 | 2021 | 65 | 0.180 |
Why?
|
| Hematologic Diseases | 1 | 2020 | 78 | 0.170 |
Why?
|
| Videoconferencing | 1 | 2020 | 15 | 0.170 |
Why?
|
| Nuclear Proteins | 1 | 2024 | 728 | 0.170 |
Why?
|
| Allografts | 1 | 2021 | 190 | 0.170 |
Why?
|
| Triage | 1 | 2021 | 118 | 0.170 |
Why?
|
| Infection Control | 1 | 2021 | 124 | 0.170 |
Why?
|
| Prognosis | 3 | 2024 | 3810 | 0.170 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 403 | 0.160 |
Why?
|
| Cross Infection | 1 | 2021 | 151 | 0.160 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 206 | 0.160 |
Why?
|
| Amyloidosis | 1 | 2021 | 130 | 0.160 |
Why?
|
| Radial Artery | 1 | 2018 | 33 | 0.160 |
Why?
|
| Leukemia | 1 | 2021 | 320 | 0.160 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2020 | 309 | 0.150 |
Why?
|
| Electromyography | 1 | 2018 | 195 | 0.150 |
Why?
|
| Disease Management | 1 | 2020 | 332 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 283 | 0.150 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 131 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2020 | 878 | 0.140 |
Why?
|
| Tissue Donors | 1 | 2020 | 511 | 0.140 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 1228 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 6812 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 2523 | 0.130 |
Why?
|
| Female | 5 | 2024 | 46855 | 0.130 |
Why?
|
| Thrombosis | 1 | 2018 | 312 | 0.130 |
Why?
|
| Prospective Studies | 1 | 2024 | 4345 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2024 | 8373 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2024 | 9323 | 0.120 |
Why?
|
| Tympanic Membrane | 1 | 2013 | 13 | 0.110 |
Why?
|
| Facial Paralysis | 1 | 2013 | 17 | 0.110 |
Why?
|
| Ciprofloxacin | 1 | 2013 | 30 | 0.110 |
Why?
|
| Mastoid | 1 | 2013 | 17 | 0.110 |
Why?
|
| Osteomyelitis | 1 | 2013 | 55 | 0.110 |
Why?
|
| Edema | 1 | 2013 | 71 | 0.110 |
Why?
|
| Temporal Bone | 1 | 2013 | 69 | 0.100 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 99 | 0.100 |
Why?
|
| Young Adult | 2 | 2024 | 6425 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2667 | 0.100 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 203 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 806 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1357 | 0.070 |
Why?
|
| Neoplasms | 1 | 2021 | 3029 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2702 | 0.050 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2023 | 131 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 104 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 143 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2023 | 316 | 0.050 |
Why?
|
| Myeloproliferative Disorders | 1 | 2024 | 135 | 0.050 |
Why?
|
| Remission Induction | 1 | 2022 | 745 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 610 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 589 | 0.040 |
Why?
|
| United States | 1 | 2024 | 7142 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 9353 | 0.020 |
Why?
|